Key result
Treatment with the GHRH antagonist MIA-602 significantly reduced triglyceride-rich lipoproteins and markers of renal injury, and improved endothelial-dependent vasorelaxation in T1D rats.
Why the study?
Does the GHRH antagonist MIA-602 reduce triglyceride-rich lipoproteins and improve renal and vascular complications in a rat model of type 1 diabetes?
Does the GHRH antagonist MIA-602 reduce triglyceride-rich lipoproteins and improve renal and vascular complications in a rat model of type 1 diabetes?
Antagonizing GHRH signaling in experimental type 1 diabetes reduces triglyceride-rich lipoproteins and improves vascular and renal complications, potentially via a GLP-1-dependent mechanism.
Authors
No takes yet. Share an insight, caveat, or question.
Hypothesis-generating for GHRH antagonism in T1D complications; leaves open translation to human disease.
Romero et al. (2016) studied Type 1 diabetes. MIA-602 (GHRH antagonist) was evaluated on Triglyceride-rich lipoproteins (TRL), markers of renal injury, and endothelial-dependent vasorelaxation. Treatment with the GHRH antagonist MIA-602 significantly reduced triglyceride-rich lipoproteins and markers of renal injury, and improved endothelial-dependent vasorelaxation in T1D rats.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: